FDA GOOD REVIEW PRACTICES COMMITTEE WILL INITIATE "ACTION PLAN"
FDA GOOD REVIEW PRACTICES COMMITTEE WILL INITIATE "ACTION PLAN" at a break-out meeting set for Nov. 21, a Nov. 3 summary of the GRP initiative prepared by Office of Drug Evaluation I Director Temple and special assistant to the Center for Drug Evaluation and Research Director Jeffrey Yorke states. The meeting will also feature discussion of "the results of the initial workshops" and will "solicit input on the project from staff involved in the review of INDs, NDAs, and PLAs," the summary notes.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth